European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Optimal dose for Stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose
Purpose: Prognosis of uterine cervical adenocarcinoma in locally advanced stage treated with radiation therapy has been considered to be much worse than that of squamous cell carcinoma because the optimal dose for the former one has not been determined. Thus, the current study was performed to investigate the optimal dose for Stage IIIB, locally advanced stage, adenocarcinoma of the uterine cervix on the basis of the biological effective dose (BED). Methods: One-hundred and seventy-nine patients with Stage IIIB carcinoma of the uterine cervix were treated with curative intended therapy at Kitasato University Hospital between 1976 and 2000. Out of them, 13 patients had an adenocarcinoma component in pathological findings. Nine patients were diagnosed with adenocarcinoma and four patients were diagnosed with adenosquamous cell carcinoma. All patients were treated with external radiation therapy combined with intracavitary radiation therapy. The total BED10 (T-BED10) was caluculated from the BED of the external beam radiation therapy (E-BED10) plus the BED of the intracavitary radiation therapy (A-BED). Results: Overall survival rate was 51 %. Stratified by T-BED10, overall survival rate of the T-BED10 ≥ 100 Gy group was 57% and that of theT-BED10 < 100 Gy group was 30%. There was a trend toward a better survival rate of the T-BED10 ≥ 100 Gy group than the T-BED10 < 100 Gy group. Conclusion: The current study suggested that the optimal dose for Stage IIIB adenocarcinoma of the uterine cervix might be TBED10 ≥ 100 Gy.